Skip to main navigation Welcome to the Biogen Newsroom Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories. View All News blue SEE LATEST NEWS Latest News NOVEMBER 22, 2021 Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa). NOVEMBER 17, 2021 Update on Regulatory Review of Aducanumab in the European Union CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s NOVEMBER 16, 2021 The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapies Phase 3 data have demonstrated that treatment with VUMERITY results in low discontinuation rates View All News SEARCH FOR MORE NEWS See Our Latest Tweets View All Twitter VIEW OUR TWITTER Biogen Statements See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives. READ MORE Annual Report Review our annual reports to see performance highlights, financials, SEC filings, stock information and more. READ MORE Sustainability Report: 2020 Year in Review Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities. READ MORE Innovation in Alzheimer's We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen. View All Alzheimer VISIT RESOURCE CENTER The Alzheimer’s Puzzle: Unlocking the Science From imaging that enables us to see amyloid and tau in the brain and determine whether potential therapeutics reach their targets, to one big leap of faith that antibodies can get into the brain, our scientists are not giving up on solving the Alzheimer’s puzzle. Healthy Climate, Healthy Lives™ Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity. READ MORE Diversity, Equity and Inclusion We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve. READ MORE Our Commitment to Corporate Responsibility Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive. READ MORE Request Multimedia Resources For Media Professionals Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need. GET IN TOUCH Get Biogen Updates Delivered to Your Inbox Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.” View All Subscribe SUBSCRIBE NOW Sign Up for Biogen Alerts Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts. View All Alerts SIGN UP FOR ALERTS Footer Links Investors Careers News Releases Our Stories Receive Our Updates Contact Us Follow us: Legal Community Guidelines Cookie Policy Forward-Looking Statement Notice to CA Residents Privacy Policy Terms & Conditions © 2021 Biogen